23 Jul 2020 13:00
Β
Β
Β
VALIRX PLC
("ValiRx", the "Company" or the "Group")
Β
Result of AGM
Β
ValiRx Plc (AIM: VAL) announces that at its Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.
Β
The proxy votes are set out below:-
Β
Resolutions | For | Against | Discretion |
Resolution 1 - Receive the annual report and accounts | 4,612,178 | 0 | 2,000 |
Resolution 2 - Re-appoint Gerry Desler as a director | 4,226,311 | 377,739 | 2,000 |
Resolution 3 - Re-appoint Dr Suzanne Dilly as a director | 4,579,542 | 23,437 | 2,000 |
Resolution 4 - Re-appoint Martin Lampshire as a director | 4,579,542 | 24,623 | 2,000 |
Resolution 5 - Re-appoint Dr Kevin Cox as a director | 4,580,958 | 23,207 | 2,000 |
Resolution 6 - Re-appoint the auditors | 4,573,342 | 26,058 | 2,000 |
Resolution 7 - Set the auditors' remuneration | 4,548,033 | 49,943 | 2,000 |
Resolution 8 - Provide authority to allot share capital | 4,441,339 | 62,857 | 2,008 |
Resolution 9 - Provide authority to dis-apply statutory pre-emption rights (Special Resolution) | 4,436,339 | 67,857 | 2,008 |
Β
Β
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
Β
*** ENDS ***
Β
For more information, please contact:
Β
ValiRx plc | Tel: +44 (0) 20 7073 2628 www.valirx.com |
Suzanne Dilly | Suzanne.Dilly@valirx.com |
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner / Ludovico Lazzaretti | Tel: +44 (0) 20 7213 0880 |
Peterhouse Capital Limited (Sole Broker) Duncan Vasey / Lucy Williams / Eran Zucker | Tel: +44 (0) 20 7469 0930 |
Β
Β
Notes for Editors
Β
About ValiRx
Β
ValiRx PLC accelerates the development of innovative medicines that enhance patient experience. We do this by combining intellectual and financial resources to select, progress and partner a balanced portfolio of risk-reduced, early-stage technologies for translation into clinical candidates.
Β
The Company listed on the AIM Market of the London StockΒ Exchange in October 2006 and trades under the ticker symbol: VAL.
Follow the stocks